^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IGH (Immunoglobulin Heavy Locus)

    i
    Apply
    Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study (NCT04269902)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/02/2021
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    TP53 • IGH
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab)
    Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies (NCT04959175)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/23/2021
    Primary completion :
    04/27/2027
    Completion :
    04/30/2027
    EGFR • IGH
    |
    cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous
    Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (NCT05470491)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    01/26/2023
    Primary completion :
    07/30/2026
    Completion :
    07/30/2027
    IGH
    |
    bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor
    Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE) (NCT04008706)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    09/17/2019
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    TP53 • CD20 • IGH • CD5 • FCER2
    |
    Chr del(17p) • Chr del(11q) • IGH mutation
    |
    Calquence (acalabrutinib)
    CLL Therapy Approaches in Russia (CLL registry) (NCT05140369)
    Phase N/A
    AstraZeneca
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/29/2021
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    TP53 • IGH
    |
    TP53 mutation
    Optimizing PTCy Dose and Timing (NCT03983850)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/09/2019
    Primary completion :
    05/31/2025
    Completion :
    05/29/2026
    KRAS • PTEN • IGH • FBXW7
    |
    KRAS mutation • RAS mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous
    A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). (NCT05947851)
    Phase 3
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/08/2023
    Primary completion :
    06/27/2033
    Completion :
    06/27/2033
    TP53 • BTK • IGH
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • nemtabrutinib (MK-1026)
    Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia (NCT02629809)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    03/18/2016
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    IGH
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04169737)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    07/29/2020
    Primary completion :
    07/09/2026
    Completion :
    07/09/2026
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q)
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (ECOG-ACRIN E1910) (NCT02003222)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    05/19/2014
    Primary completion :
    06/23/2023
    Completion :
    03/14/2025
    ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia (NCI-2016-00797) (NCT02756897)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    07/07/2016
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT01243190)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    09/19/2024
    Initiation :
    03/01/2011
    Primary completion :
    03/28/2023
    Completion :
    03/28/2023
    IGH • CD38
    |
    CD38 positive
    |
    Arzerra (ofatumumab)
    A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) (NCT05624554)
    Phase 3
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    03/16/2023
    Primary completion :
    05/19/2027
    Completion :
    03/17/2031
    TP53 • IGH
    |
    IGH mutation
    |
    cyclophosphamide • bendamustine • Truxima (rituximab-abbs) • fludarabine IV • nemtabrutinib (MK-1026)
    PICAROS - Acalabrutinib RWE on 1L CLL in Spain (NCT05999877)
    Phase N/A
    AstraZeneca
    Active, not recruiting
    Last update posted :
    06/12/2024
    Initiation :
    07/11/2023
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    TP53 • IGH
    |
    TP53 mutation + Chr del(17p)
    |
    Calquence (acalabrutinib)
    Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (ECOG-ACRIN E1912) (NCT02048813)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    02/20/2014
    Primary completion :
    10/24/2018
    Completion :
    12/31/2024
    CD20 • CCND1 • IGH • CD4 • CD5 • FCER2
    |
    Chr t(11;14) • CD4 positive
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • cyclophosphamide • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma (NCT04850846)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    04/27/2021
    Primary completion :
    01/31/2025
    Completion :
    07/31/2025
    IGH
    |
    metformin
    The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (NCT05436418)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    11/18/2022
    Primary completion :
    06/25/2027
    Completion :
    07/02/2027
    IGH • HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies (NCT02443831)
    Phase 1
    University College, London
    Active, not recruiting
    Last update posted :
    05/30/2024
    Initiation :
    04/01/2016
    Primary completion :
    12/31/2028
    Completion :
    12/31/2036
    ABL1 • BCR • KMT2A • IGH • CD22 • TCF3
    |
    KMT2A rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous
    A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. (NCT03219450)
    Phase 1
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    08/18/2021
    Primary completion :
    03/31/2026
    Completion :
    03/31/2028
    IGH
    |
    IGH mutation
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Neo Vax (NEO-PV-01) • cyclophosphamide intravenous
    CAR-37 T Cells In Hematologic Malignancies (NCT04136275)
    Phase 1
    Marcela V. Maus, M.D.,Ph.D.
    Completed
    Last update posted :
    03/13/2024
    Initiation :
    06/19/2020
    Primary completion :
    09/30/2023
    Completion :
    03/01/2024
    TP53 • IGH • CD5 • CD37
    |
    TP53 mutation • CD37 expression
    A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT04501614)
    Phase 1/2
    Takeda
    Active, not recruiting
    Last update posted :
    03/04/2024
    Initiation :
    02/24/2021
    Primary completion :
    12/19/2024
    Completion :
    01/04/2027
    ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4
    |
    BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation
    |
    cytarabine • Iclusig (ponatinib) • cyclophosphamide
    Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (NCI-2011-03562) (NCT01527149)
    Phase 2
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    02/07/2024
    Initiation :
    12/06/2011
    Primary completion :
    04/26/2018
    Completion :
    01/11/2024
    CD20 • CCND1 • IGH • CD5 • FCER2
    |
    Chr t(11;14) • CD20 expression
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Arzerra (ofatumumab) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV
    Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT05388006)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    01/09/2024
    Initiation :
    06/15/2022
    Primary completion :
    11/15/2024
    Completion :
    11/15/2025
    CD20 • CCND1 • IGH • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Imfinzi (durvalumab) • Calquence (acalabrutinib)
    Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT02332980)
    Phase 2
    Mayo Clinic
    Completed
    Last update posted :
    01/03/2024
    Initiation :
    02/19/2015
    Primary completion :
    08/10/2021
    Completion :
    01/04/2022
    CD20 • PD-1 • CCND1 • IGH • PD-L2 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • Zydelig (idelalisib)
    Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL (VIS) (NCT05478512)
    Phase 2
    Gruppo Italiano Malattie EMatologiche dell'Adulto
    Recruiting
    Last update posted :
    11/18/2023
    Initiation :
    07/21/2023
    Primary completion :
    05/01/2026
    Completion :
    07/01/2027
    TP53 • IGH
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia (NCT05943496)
    Phase 1
    OHSU Knight Cancer Institute
    Recruiting
    Last update posted :
    11/03/2023
    Initiation :
    10/02/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    IGH
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib) • Monjuvi (tafasitamab-cxix)
    Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara (NCT03896737)
    Phase 2
    European Myeloma Network
    Active, not recruiting
    Last update posted :
    09/07/2023
    Initiation :
    04/16/2019
    Primary completion :
    05/01/2024
    Completion :
    02/01/2025
    IGH
    |
    IGH translocation
    |
    bortezomib • cyclophosphamide • Ninlaro (ixazomib) • Darzalex (daratumumab) • thalidomide • melphalan • cyclophosphamide intravenous
    Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma (NCT05037669)
    Phase 1
    University of Pennsylvania
    Withdrawn
    Last update posted :
    06/22/2023
    Initiation :
    07/01/2022
    Primary completion :
    01/01/2025
    Completion :
    01/01/2038
    ALK • BCL2 • CD19 • BCL6 • IGH
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    Kymriah (tisagenlecleucel-T)
    STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR) (NCT04963946)
    Phase 2
    French Innovative Leukemia Organisation
    Recruiting
    Last update posted :
    05/24/2023
    Initiation :
    10/18/2021
    Primary completion :
    04/15/2024
    Completion :
    12/31/2026
    TP53 • IGH
    |
    TP53 mutation • IGH mutation
    |
    Calquence (acalabrutinib)
    Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. (NCT03939234)
    Phase 2
    Lars Møller Pedersen
    Completed
    Last update posted :
    02/21/2022
    Initiation :
    04/26/2019
    Primary completion :
    03/15/2021
    Completion :
    03/15/2021
    IGH
    |
    IO103 • IO120
    A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy (NCT01556776)
    Phase 3
    German CLL Study Group
    Completed
    Last update posted :
    01/05/2022
    Initiation :
    07/20/2012
    Primary completion :
    03/01/2016
    Completion :
    01/14/2021
    TP53 • IGH
    |
    TP53 mutation
    |
    lenalidomide
    Phase III B in Acute Lymphoblastic Leukemia (NCT03123939)
    Phase 3
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    07/21/2021
    Initiation :
    04/24/2017
    Primary completion :
    10/13/2020
    Completion :
    10/13/2020
    ABL1 • BCR • CD19 • CD8 • IGH • CD4
    |
    CD19 expression
    |
    Kymriah (tisagenlecleucel-T)
    Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients (NCT04691765)
    Phase 1
    Dr. David Spaner
    Not yet recruiting
    Last update posted :
    03/19/2021
    Initiation :
    05/01/2021
    Primary completion :
    12/01/2021
    Completion :
    12/01/2022
    CD20 • IGH • CD5
    |
    Kineret (anakinra)
    A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (iLLUMINATE ) (NCT02264574)
    Phase 3
    Pharmacyclics LLC.
    Completed
    Last update posted :
    09/21/2020
    Initiation :
    10/06/2014
    Primary completion :
    03/26/2018
    Completion :
    09/03/2019
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Leukeran (chlorambucil)
    Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia (NCT01269385)
    Phase 1/2
    Mayo Clinic
    Completed
    Last update posted :
    06/23/2020
    Initiation :
    01/01/2011
    Primary completion :
    06/01/2014
    Completion :
    06/01/2015
    CD20 • CCND1 • IGH • CD38 • CD5 • FCER2
    |
    CD38 expression • CD20 expression
    |
    Rituxan (rituximab) • Campath (alemtuzumab) • Imprime PGG (odetiglucan)
    Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients (NCT02481297)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/28/2020
    Initiation :
    06/23/2015
    Primary completion :
    08/15/2019
    Completion :
    08/15/2019
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q)
    |
    Rituxan (rituximab) • lirilumab (BMS-986015)
    Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing Workflow (NCT02788084)
    Phase N/A
    Alberta Health Services, Calgary
    Unknown status
    Last update posted :
    01/10/2020
    Initiation :
    10/01/2016
    Primary completion :
    06/01/2019
    Completion :
    06/01/2021
    IGH
    Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia (NCT01460238)
    Phase N/A
    Dartmouth-Hitchcock Medical Center
    Completed
    Last update posted :
    03/28/2019
    Initiation :
    10/01/2011
    Primary completion :
    05/01/2018
    Completion :
    05/01/2018
    IGH
    |
    IGH mutation